Pegfilgrastim: a recent advance in the prophylaxis of chemotherapy-induced neutropenia.
Identifieur interne : 000735 ( PubMed/Corpus ); précédent : 000734; suivant : 000736Pegfilgrastim: a recent advance in the prophylaxis of chemotherapy-induced neutropenia.
Auteurs : A-R WaladkhaniSource :
- European journal of cancer care [ 0961-5423 ] ; 2004.
English descriptors
- KwdEn :
- Antineoplastic Agents (adverse effects), Clinical Trials as Topic, Filgrastim, Granulocyte Colony-Stimulating Factor (analogs & derivatives), Granulocyte Colony-Stimulating Factor (therapeutic use), Hematologic Agents (therapeutic use), Humans, Neoplasms (complications), Neoplasms (drug therapy), Neutropenia (chemically induced), Neutropenia (drug therapy), Neutropenia (prevention & control), Recombinant Proteins, Treatment Outcome.
- MESH :
- chemical , adverse effects : Antineoplastic Agents.
- chemical , analogs & derivatives : Granulocyte Colony-Stimulating Factor.
- chemical , therapeutic use : Granulocyte Colony-Stimulating Factor, Hematologic Agents.
- chemically induced : Neutropenia.
- complications : Neoplasms.
- drug therapy : Neoplasms, Neutropenia.
- prevention & control : Neutropenia.
- Clinical Trials as Topic, Filgrastim, Humans, Recombinant Proteins, Treatment Outcome.
Abstract
Chemotherapy-induced neutropenia is a frequent complication in cancer patients receiving myelosuppressive chemotherapy. Chemotherapy-induced neutropenia can result in febrile neutropenia and potentially life-threatening infections requiring hospitalization and intravenous anti-infectives. Chemotherapy dose may be reduced or delayed as a result of chemotherapy-induced neutropenia, which can negatively impact treatment outcomes. Granulocyte colony-stimulating factors, such as filgrastim, stimulate neutrophil production and can therefore reduce the incidence and severity of chemotherapy-induced neutropenia. Filgrastim undergoes rapid renal clearance and needs to be administered daily. The development of pegfilgrastim represents a significant advance in the management of chemotherapy-induced neutropenia as the longer serum half-life allows once-per-chemotherapy administration, and evidence supports increased prophylactic effectiveness in reducing the incidence of febrile neutropenia. This paper reviews the development of pegfilgrastim and summarizes recent clinical data on the use of this simple, effective and well-tolerated option for the management of chemotherapy-induced neutropenia in patients with cancer.
DOI: 10.1111/j.1365-2354.2004.00503.x
PubMed: 15305906
Links to Exploration step
pubmed:15305906Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Pegfilgrastim: a recent advance in the prophylaxis of chemotherapy-induced neutropenia.</title><author><name sortKey="Waladkhani, A R" sort="Waladkhani, A R" uniqKey="Waladkhani A" first="A-R" last="Waladkhani">A-R Waladkhani</name><affiliation><nlm:affiliation>Krankenanstalt Mutterhaus der Borromäerinnen, Medizinsche Abteilung I, Trier, Germany. waladkha@uni-trier.de</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2004">2004</date><idno type="RBID">pubmed:15305906</idno><idno type="pmid">15305906</idno><idno type="doi">10.1111/j.1365-2354.2004.00503.x</idno><idno type="wicri:Area/PubMed/Corpus">000735</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000735</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Pegfilgrastim: a recent advance in the prophylaxis of chemotherapy-induced neutropenia.</title><author><name sortKey="Waladkhani, A R" sort="Waladkhani, A R" uniqKey="Waladkhani A" first="A-R" last="Waladkhani">A-R Waladkhani</name><affiliation><nlm:affiliation>Krankenanstalt Mutterhaus der Borromäerinnen, Medizinsche Abteilung I, Trier, Germany. waladkha@uni-trier.de</nlm:affiliation></affiliation></author></analytic><series><title level="j">European journal of cancer care</title><idno type="ISSN">0961-5423</idno><imprint><date when="2004" type="published">2004</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic Agents (adverse effects)</term><term>Clinical Trials as Topic</term><term>Filgrastim</term><term>Granulocyte Colony-Stimulating Factor (analogs & derivatives)</term><term>Granulocyte Colony-Stimulating Factor (therapeutic use)</term><term>Hematologic Agents (therapeutic use)</term><term>Humans</term><term>Neoplasms (complications)</term><term>Neoplasms (drug therapy)</term><term>Neutropenia (chemically induced)</term><term>Neutropenia (drug therapy)</term><term>Neutropenia (prevention & control)</term><term>Recombinant Proteins</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Granulocyte Colony-Stimulating Factor</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Granulocyte Colony-Stimulating Factor</term><term>Hematologic Agents</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Neutropenia</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Neoplasms</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Neoplasms</term><term>Neutropenia</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Neutropenia</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Clinical Trials as Topic</term><term>Filgrastim</term><term>Humans</term><term>Recombinant Proteins</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Chemotherapy-induced neutropenia is a frequent complication in cancer patients receiving myelosuppressive chemotherapy. Chemotherapy-induced neutropenia can result in febrile neutropenia and potentially life-threatening infections requiring hospitalization and intravenous anti-infectives. Chemotherapy dose may be reduced or delayed as a result of chemotherapy-induced neutropenia, which can negatively impact treatment outcomes. Granulocyte colony-stimulating factors, such as filgrastim, stimulate neutrophil production and can therefore reduce the incidence and severity of chemotherapy-induced neutropenia. Filgrastim undergoes rapid renal clearance and needs to be administered daily. The development of pegfilgrastim represents a significant advance in the management of chemotherapy-induced neutropenia as the longer serum half-life allows once-per-chemotherapy administration, and evidence supports increased prophylactic effectiveness in reducing the incidence of febrile neutropenia. This paper reviews the development of pegfilgrastim and summarizes recent clinical data on the use of this simple, effective and well-tolerated option for the management of chemotherapy-induced neutropenia in patients with cancer.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15305906</PMID><DateCreated><Year>2004</Year><Month>08</Month><Day>12</Day></DateCreated><DateCompleted><Year>2005</Year><Month>03</Month><Day>10</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0961-5423</ISSN><JournalIssue CitedMedium="Print"><Volume>13</Volume><Issue>4</Issue><PubDate><Year>2004</Year><Month>Sep</Month></PubDate></JournalIssue><Title>European journal of cancer care</Title><ISOAbbreviation>Eur J Cancer Care (Engl)</ISOAbbreviation></Journal><ArticleTitle>Pegfilgrastim: a recent advance in the prophylaxis of chemotherapy-induced neutropenia.</ArticleTitle><Pagination><MedlinePgn>371-9</MedlinePgn></Pagination><Abstract><AbstractText>Chemotherapy-induced neutropenia is a frequent complication in cancer patients receiving myelosuppressive chemotherapy. Chemotherapy-induced neutropenia can result in febrile neutropenia and potentially life-threatening infections requiring hospitalization and intravenous anti-infectives. Chemotherapy dose may be reduced or delayed as a result of chemotherapy-induced neutropenia, which can negatively impact treatment outcomes. Granulocyte colony-stimulating factors, such as filgrastim, stimulate neutrophil production and can therefore reduce the incidence and severity of chemotherapy-induced neutropenia. Filgrastim undergoes rapid renal clearance and needs to be administered daily. The development of pegfilgrastim represents a significant advance in the management of chemotherapy-induced neutropenia as the longer serum half-life allows once-per-chemotherapy administration, and evidence supports increased prophylactic effectiveness in reducing the incidence of febrile neutropenia. This paper reviews the development of pegfilgrastim and summarizes recent clinical data on the use of this simple, effective and well-tolerated option for the management of chemotherapy-induced neutropenia in patients with cancer.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Waladkhani</LastName><ForeName>A-R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Krankenanstalt Mutterhaus der Borromäerinnen, Medizinsche Abteilung I, Trier, Germany. waladkha@uni-trier.de</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Cancer Care (Engl)</MedlineTA><NlmUniqueID>9301979</NlmUniqueID><ISSNLinking>0961-5423</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006401">Hematologic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>143011-72-7</RegistryNumber><NameOfSubstance UI="D016179">Granulocyte Colony-Stimulating Factor</NameOfSubstance></Chemical><Chemical><RegistryNumber>3A58010674</RegistryNumber><NameOfSubstance UI="C455861">pegfilgrastim</NameOfSubstance></Chemical><Chemical><RegistryNumber>PVI5M0M1GW</RegistryNumber><NameOfSubstance UI="D000069585">Filgrastim</NameOfSubstance></Chemical></ChemicalList><CitationSubset>N</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069585" MajorTopicYN="N">Filgrastim</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016179" MajorTopicYN="N">Granulocyte Colony-Stimulating Factor</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs & derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006401" MajorTopicYN="N">Hematologic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009503" MajorTopicYN="N">Neutropenia</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>38</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>8</Month><Day>13</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>3</Month><Day>11</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>8</Month><Day>13</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15305906</ArticleId><ArticleId IdType="doi">10.1111/j.1365-2354.2004.00503.x</ArticleId><ArticleId IdType="pii">ECC503</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Rhénanie/explor/UnivTrevesV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000735 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000735 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Rhénanie
|area= UnivTrevesV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:15305906
|texte= Pegfilgrastim: a recent advance in the prophylaxis of chemotherapy-induced neutropenia.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:15305906" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a UnivTrevesV1
| This area was generated with Dilib version V0.6.31. |  |